Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have received a consensus broker rating score of 3.00 (Hold) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong sell recommendation and one has assigned a strong buy recommendation to the company. Akari Therapeutics PLC’s rating score has improved by 40% from three months ago as a result of a number of analysts’ ratings changes.
Brokerages have set a one year consensus target price of $5.00 for the company and are expecting that the company will post ($0.54) EPS for the current quarter, according to Zacks. Zacks has also assigned Akari Therapeutics PLC an industry rank of 152 out of 265 based on the ratings given to its competitors.
Several equities analysts recently commented on AKTX shares. William Blair reiterated an “outperform” rating on shares of Akari Therapeutics PLC in a research note on Thursday, April 6th. Zacks Investment Research upgraded Akari Therapeutics PLC from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research note on Friday, March 24th. Finally, Chardan Capital dropped their target price on Akari Therapeutics PLC from $6.50 to $5.00 and set a “sell” rating for the company in a research note on Monday, April 17th.
TRADEMARK VIOLATION WARNING: This report was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://transcriptdaily.com/2017/05/20/brokerages-set-5-00-target-price-for-akari-therapeutics-plc-aktx-updated-updated-updated.html.
An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Baker BROS. Advisors LP purchased a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 496,901 shares of the biopharmaceutical company’s stock, valued at approximately $4,229,000. 34.02% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Akari Therapeutics PLC (NASDAQ:AKTX) traded down 4.74% during mid-day trading on Monday, hitting $10.65. The company’s stock had a trading volume of 44,843 shares. The company’s market cap is $125.41 million. Akari Therapeutics PLC has a 12-month low of $6.22 and a 12-month high of $22.20. The stock has a 50-day moving average of $12.87 and a 200-day moving average of $8.87.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.